Racks Biotech

The third guidance lift this year signals that oral GLP-1 demand is holding up even as Eli Lilly widens its lead in the weight-loss market.

Lilly's obesity franchise has pulled well ahead of its main rival, intensifying competition as both companies push pill formulations and new indications.

The raise shows Pfizer's post-pandemic reset is taking hold, with growth from acquired oncology assets and its anticoagulant replacing declining Covid revenue.

The preclinical claim, based on animal data only, positions the Korean company as a new entrant in an increasingly crowded next-generation obesity race.

Advisory panel support is a key step toward U.S. approval for the multi-cancer blood test, a product whose commercial future has been closely watched since GRAIL's spinoff.

The lawsuit raises questions about the safety profile of the first approved MASH therapy, a key growth product for Madrigal.

Investigator lobbying ahead of a regulatory decision signals unusually high stakes for the Duchenne muscular dystrophy cell therapy.

The pharma critic's influence over FDA appropriations could shape agency policy and drug-pricing politics in the next funding cycle.

Analysts argue that most-favored-nation pricing is already priced into the sector, limiting the downside from a Democratic sweep.

The roundup covers a major corporate restructuring at CVS and Bayer's response to U.S. drug-pricing pressure.

A filing acceptance would set up a potential approval in an inflammatory skin condition where competition is growing.

The finding highlights how employer purchasing decisions increasingly favor cheaper benefits over clinical value, pressuring drugmakers' pricing strategies.

The uptake figure offers early commercial traction data for a gene therapy targeting recurrent respiratory papillomatosis.

The collaboration adds analytical backing to Hanmi's late-stage obesity program as Korean developers push into the global metabolic market.

The response rate applies to a biomarker-selected subgroup, a common design in oncology trials that can limit how broadly results generalize.

The dose-escalation milestone is an early sign of tolerability for the program, though efficacy remains unknown until 2027 readouts.

The two-patient result is very early evidence for cell therapy in lupus nephritis, a condition with limited treatment options.

The update covers the company's pipeline and cash position as it develops its lead oncology candidate.

The rollout marks another market where oral GLP-1 competition is shifting from injections to pills.

The company is betting on consumer brand building in a market where local GLP-1 makers hold a cost advantage.

Prescription start-form counts give an early read on launch uptake for the therapy.

A review of Lilly's dealmaking and pipeline cuts shows how the company is reshuffling resources around metabolic disease and other priority areas.

The ranking illustrates concentration of revenue among a handful of blockbuster products in a trillion-dollar market.

The webcast gives investors a scheduled update on the ophthalmic drug developer's pipeline and finances.

The scheduled report covers the medical-device company's fiscal third quarter.